6 completed, 6 recruiting, 4 unknown, 2 terminated. 21 Phase 2, 9 Phase 1, 1 Phase 3.
Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients SWA (standardized root extract of Withania somnifera) - Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Recruiting | Tata Memorial Centre | 54 | 2025-01-28 | 2026-07-24 |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections - Hematological Malignancy, Lymphocytopenia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 50 | 2024-09-01 | 2024-09-19 |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells - Hematological Malignancy | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 64 | 2024-04-22 | 2026-08-20 |
| PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Thymoglobulin Injectable Product - Hematological Malignancy | Phase 2 | Unknown | Institut Paoli-Calmettes | 27 | 2024-03-31 | 2024-02-20 |
| Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia Eravacycline - Hematological Malignancy, Neutropenia | Phase 2 | Recruiting | West Virginia University | 55 | 2024-02-19 | 2026-04-16 |
| Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. Standardized Withaferin A (SWA) - Hematological Malignancy, GVHD - Graft-Versus-Host Disease | Phase 2 | Recruiting | Tata Memorial Centre | 34 | 2023-09-23 | 2026-07-16 |
| Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours CAR-T cell therapy - Hematological Malignancy | Phase 2 / Phase 3 | Unknown | Shanxi Bethune Hospital | 30 | 2020-06-15 | 2024-02-02 |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 BMS-986253 - Solid Tumor, Sars-CoV2 | Phase 2 | Terminated | Columbia University | 43 | 2020-04-16 | 2025-05-22 |
| Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Pembrolizumab, Ruxolitinib - Cancer, Hematological Malignancy | Phase 2 | Withdrawn | NYU Langone Health | 2019-12-01 | 2020-05-27 | |
| Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2019-09-15 | 2022-04-13 |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation Evomela, Fludarabine, Total Body Irradiation - Hematological Malignancy, Multiple Myeloma | Phase 2 | Completed | Medical College of Wisconsin | 43 | 2017-12-08 | 2026-01-27 |
| HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Bortezomib - Hematological Malignancy | Phase 2 | Recruiting | Henry Ford Health System | 15 | 2016-03-08 | 2026-02-24 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL MT-3724 Phase 1, MT-3724 Phase 2 - Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Terminated | Molecular Templates, Inc. | 38 | 2015-02-01 | 2022-08-18 |
| Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Eltrombopag - Hematological Malignancy, Bone Marrow Failure Syndrome | Phase 2 | Unknown | Rabin Medical Center | 20 | 2013-01-01 | 2015-06-19 |
| Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®) - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Corewell Health West | 28 | 2012-04-01 | 2023-06-02 |
| A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy AlloStim - Hematological Malignancy, Leukemia | Phase 1 / Phase 2 | Completed | Mirror Biologics, Inc. | 6 | 2010-12-01 | 2020-01-22 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Isatuximab SAR650984, Dexamethasone - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Sanofi | 351 | 2010-05-11 | 2024-11-01 |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation donor lymphocyte infusion - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2010-02-01 | 2013-01-14 |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation reduced intensity conditionings - Allograft, Allogeneic Cell Transplantaion | Phase 2 | Completed | Institut Paoli-Calmettes | 148 | 2002-11-01 | 2014-01-01 |
Showing 20 of 21. Sign in to see all of them.
Hematologic Neoplasms (21) · Graft vs Host Disease (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Neoplasms (2) · Recurrence (2) · Bone Marrow Failure Disorders (1) · COVID-19 (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Hematologic Diseases (1) · Hodgkin Disease (1)
Hemic and Lymphatic Diseases (21) · Neoplasms by Site (21) · Hematologic Diseases (20) · Neoplasms (19) · Immune System Diseases (6) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms by Histologic Type (4) · Disease Attributes (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Blood Protein Disorders (2) · Bone Marrow Diseases (2) · Cardiovascular Diseases (2) · Chronic Disease (2)
Cyclophosphamide (3) · Bortezomib (2) · fludarabine (2) · fludarabine phosphate (2) · Dexamethasone (1) · Etanercept (1) · HuMax-IL8 (1) · Immunotherapy, Adoptive (1) · Infliximab (1) · Injections (1) · Melphalan (1) · Metoprolol (1) · Thymalfasin (1) · Whole-Body Irradiation (1) · eltrombopag (1)
Institut Paoli-Calmettes (2) · Tata Memorial Centre (2) · Assistance Publique - Hôpitaux de Paris (1) · Chinese PLA General Hospital (1) · Columbia University (1) · Corewell Health West (1) · Hadassah Medical Organization (1) · Henry Ford Health System (1) · M.D. Anderson Cancer Center (1) · Medical College of Wisconsin (1) · Mirror Biologics, Inc. (1) · Molecular Templates, Inc. (1) · NYU Langone Health (1) · Rabin Medical Center (1) · Sanofi (1)
United States (9) · Israel (5) · China (3) · France (3) · India (2) · Spain (2) · Ukraine (2) · Argentina (1) · Belarus (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Finland (1) · Georgia (1)
A. Samer Al-Homsi, MD (1) · Aaron Cumpston, PharmD, BCOP (1) · Dr. Michael Har-Noy (1) · Dr.Akanksha Chichra, DNB (1) · Mark N Stein, MD (1) · Mehdi Hamadani (1) · Moshe Yeshurun, MD (1) · Raoul Tibes, MD (1) · Shimon Slavin, MD (1) · Xiaomin Zhang (1) · Zhijuan Lin (1)
PMID 19282026, PMID 23802653, PMID 26408225, PMID 30904387, PMID 32160294, PMID 32416453, PMID 5449164, PMID 10845900, PMID 11301861, PMID 12663454, PMID 18997826, PMID 21558065, PMID 22110505, PMID 22410750, PMID 22510384, PMID 22533831, PMID 22754076, PMID 22982675, PMID 23892326, PMID 25452693, PMID 26959007, PMID 27250656, PMID 27899357, PMID 29171820, PMID 31678539, PMID 32043777, PMID 32409691, PMID 32537114, PMID 32684166, PMID 33080623, PMID 33574236, PMID 34204308, PMID 3513012, PMID 36518386, PMID 9746768